1.2701 -0.03 (-2.30%)
After hours: 6:27PM EDT
|Bid||1.2900 x 800|
|Ask||1.3500 x 900|
|Day's Range||1.2600 - 1.3700|
|52 Week Range||0.7400 - 25.6000|
|Beta (3Y Monthly)||2.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.75|
“We had a commercial team, a marketing team, and the sales organization. … At the last minute, the FDA decided the data was not sufficient for approval.”
NEW ORLEANS , March 11, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed ...
Do you own shares of GTx, Inc. (NASDAQ CM: GTXI)? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of GTx, Inc. (“GTx” or the “Company”) (NASDAQ CM: GTXI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with Oncternal Therapeutics, Inc. (“Oncternal”). Under the terms of the agreement, current GTx stockholders will own approximately 25% of the combined company.
NEW YORK, March 07, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased GTx, Inc. (“GTx” or the “Company”).
CORAL GABLES, FL / ACCESSWIRE / March 7, 2019 / The healthcare stock market has gotten off to an impressive start in the first few months of 2019, as companies in the healthcare sector work to pioneer innovative drug treatment options and care solutions for the millions of patients in need. On a near daily basis, headlines detailing a company's new drug approval or a technological breakthrough emerge, indicating to potential investors that they could benefit from paying attention to the healthcare sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), GTx Inc (GTXI), Co-Diagnostics Inc (CODX), and Novavax Inc (NASDAQ:NVAX) represent 4 healthcare companies heating up on Thursday.
Oncternal does not anticipate retaining any GTx employees once the merger is completed. The biopharmaceutical firm has 27 employees — 25 of them local.
GTx, Inc. (GTXI) and Oncternal Therapeutics, Inc., a privately held clinical-stage biotechnology company developing potential first-in-class therapeutic candidates for cancers with critical unmet medical need, today jointly announced that they have entered into a definitive merger agreement under which the stockholders of Oncternal would become the majority owners of GTx’s outstanding common stock. The proposed merger will create a publicly-traded, clinical-stage oncology company. The combined company will be named Oncternal Therapeutics, Inc. and plans to change its ticker symbol on the Nasdaq Capital Market to ONCT upon closing of the transaction.
Yesterday, FedEx Logistics, a subsidiary of FedEx Corp., announced plans to move its global headquarters to the former Gibson Guitar Factory building in 2020, joining the likes of some of the area’s largest locally based public companies. To read more on FedEx Logistics and plans for the area, click here, here, or here. This news comes almost exactly a year after home services provider, ServiceMaster Global Holdings relocated its first group of employees from East Memphis to the newly renovated One ServiceMaster Center, formerly the Peabody Place mall.
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 39 cents. The company's shares closed at $1.79. A year ago, they were trading at $7.92. _____ This story was generated by ...
GTx, Inc. today reported financial results for the third quarter ended September 30, 2018, and provided a corporate update.
The more than 50 current and former executives at Memphis-based public companies earned $180 million in total compensation in 2017.
NEW YORK, NY / ACCESSWIRE / October 8, 2018 / GTx Inc. was seeing big gains on Friday despite any news. The company had recently saw its shares collapse on news that its only drug candidate had failed a mid-stage clinical trial. Shares of TrovaGene Inc. were also in the green despite any news on Friday, but it was last week that the company announced it had entered into an exclusive patent license agreement with the Massachusetts Institute of Technology.
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Shares of GTx were deep in the red on Friday on disappointing news that the company’s only drug candidate had filed a mid-stage clinical trial. Shares of Protalix BioTherapeutics on the other hand were soaring on positive preliminary data. GTx, Inc. shares closed down a little over 92% on Friday, making it one of the biggest decliners on the Nasdaq.
The company's only drug candidate failed a mid-stage clinical trial. The next clinic-ready assets are on the way -- in late 2019 or early 2020.
GTx, Inc. (GTXI) today announced that the ASTRID Trial, a Phase 2 double-blind, placebo-controlled clinical trial of orally-administered enobosarm (3 mg or 1 mg) in post-menopausal women with stress urinary incontinence (SUI), did not achieve statistical significance on the primary endpoint of the proportion of patients with a greater than 50% reduction in incontinence episodes per day compared to placebo. “We are very disappointed that the ASTRID Trial did not achieve its primary endpoint,” said Robert J. Wills, Ph.D., Executive Chairman of GTx.